ASX Announcement

Annual General Meeting

Address by Chair and Managing Director

Perth, Australia; 6 November 2026: Regenerative medicine company Orthocell Limited (ASX: OCC, "Orthocell" or "the Company") is pleased to provide copies of the addresses to be delivered by the Chair and Managing Director at today's Annual General Meeting.

Release authorised by:
Paul Anderson, Orthocell Ltd CEO and MD

For more information, please contact:

General enquiries	Media enquiries	Investor enquiries
Paul Anderson Orthocell Limited CEO and MD P: +61 8 9360 2888 E: paul.anderson@orthocell.com	**Haley Chartres** **H^CK Director** P: +61 423 139 163 E: haley@hck.digital	**Shaun Duffy** **VECTOR Advisors** P: +61 404 094 384 E: sduffy@vectoradvisors.au

About Orthocell Limited

ACN 118 897 135

Registered Office – Level 2, 161 Campus Drive, Murdoch University, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed a network of specialist US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand, Canada and Hong Kong. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @Orthocelllltd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate, "expect," "intend," "may," "plan," "predict," "project," "target, "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for is product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

From the Chair

John Van Der Wielen

Before reviewing the Company's performance, I would like to acknowledge the recent Orthocell share price performance. I recognise that many shareholders have been disappointed by the market's response despite the significant progress the Company has made over the past year.

As a shareholder myself, I share the desire to see the value we are creating reflected in the Company's market valuation.

Our responsibility is to create value. The market's responsibility is to recognise it. History shows that while those two things do not always occur at the same time, they tend to converge over the long term.

Markets do not always immediately recognise the value being built within a company. Short-term share price movements can reflect uncertainty, shifting expectations or broader market conditions rather than the underlying performance of the business. Our focus therefore remains clear: to execute our strategy, grow the business and deliver results for shareholders.

If we continue to execute successfully, I am confident the value being created within Orthocell will ultimately be recognised by the market.

When I look at Orthocell today, I see a company that has achieved a significant transformation.

Over the past twelve months, we have continued our transition from a development-stage biotechnology company to a commercial organisation. We have moved beyond many of the scientific and regulatory milestones that traditionally define emerging healthcare businesses and are now increasingly focused on commercial execution and growth.

FY2026 delivered strong revenue growth of 45% year on year, with Remplir becoming an increasingly important contributor to the business. We remain well funded with circa $39 million in cash and continue to invest in expanding our global commercial footprint.

The United States remains our most significant growth opportunity. During the year, we expanded our distributor network, increased hospital access and continued to grow the number of surgeons using and adopting Remplir.

Importantly, we are now beginning to see the benefits of those investments. October delivered our strongest month of U.S. Remplir sales since launch and early November has continued to demonstrate encouraging momentum. This momentum extrapolated over the next 6 months could deliver a very healthy top line and does so at significant margins. We are selling our own manufactured products, we

own the value chain, we do not pay royalties and we have the manufacturing capacity to deliver the planned growth in the US and other markets.

While adoption within major healthcare systems rarely follows a straight line, the commercial foundations we have established over the past year are increasingly translating into greater utilisation and revenue growth. As our growing network of surgeons gains experience with Remplir, we expect repeat usage to become an increasingly important driver of future growth.

Beyond the United States, Remplir continues to gain traction across a growing number of international markets through our capital-efficient distributor model, creating additional avenues for growth and diversification.

We are also continuing to strengthen our longer-term platform. This week's FDA clearance of PearlBone by Marine Biomedical represents an important validation of both the technology and Orthocell's strategic investment in the business. It also provides a potential pathway to broaden our regenerative medicine portfolio in the future.

What excites me most is that Orthocell today possesses many of the attributes associated with successful global healthcare companies: with two FDA-cleared best in class products addressing significant clinical needs, a growing commercial presence in the world's largest healthcare market, expanding international sales, a strong balance sheet and a clear pathway toward profitability.

Our priorities remain straightforward: increasing Remplir utilisation in the United States, expanding international sales, supporting our commercial partners and continuing to develop technologies capable of creating long-term shareholder value.

Above all, our objective is to translate the substantial progress already achieved into sustainable revenue growth and profitability. As revenue continues to increase and utilisation expands across our growing network of surgeons and hospitals, I believe Orthocell is well positioned to create meaningful long-term value for shareholders.

I remain highly confident in the quality of our products, based on science and clinical results, the strength of our team and the scale of the opportunity ahead of us. The past year has delivered important milestones, and I believe Orthocell is well positioned for its next phase of growth.

Finally, I would like to thank Paul and the entire Orthocell team, my fellow Directors, our clinicians, partners, distributors and, most importantly, our shareholders for your continued support.

We have made substantial progress over the past year. While much work remains ahead of us, I believe Orthocell is entering its next phase from a position of strength, with a clear strategy, a growing commercial platform and significant opportunities before it.

Thank you.

John Van Der Wielen



AGM Presentation

Paul Anderson
Orthocell MD and CEO

Disclaimer

This presentation, prepared by Orthocell Ltd ("Company"), does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor.

This document is confidential and has been made available in confidence. It may not be reproduced, disclosed to third parties or made public in any way or used for any purpose other than in connection with the proposed investment opportunity without the express written permission of the Company.

This presentation should not be relied upon as a representation of any matter that an advisor or potential investor should consider in evaluating the Company. The Company and its related bodies corporate or any of its directors, agents, officers or employees do not make any representation or warranty, express or implied, as to the accuracy or completeness of any information, statements or representations contained in this presentation, and they do not accept any liability whatsoever (including in negligence) for any information, representation or statement made in or omitted from this presentation.

This document contains certain forward-looking statements which involve known and unknown risks, delays and uncertainties not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. The Company makes no representation or warranty, express or implied, as to or endorsement of the accuracy or completeness of any information, statements or representations contained in this presentation with respect to the Company.

It is acknowledged that the Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

Orthocell at a Glance

Australian medical technology company with growing international revenue driven by the commercialisation of its flagship nerve repair product, Remplir™, in the ~US$2 billion U.S. market[1].



Fully funded and investing in sales growth

$39.0 million in cash reserves, and no debt.[2]

Continued investment in U.S. sales growth, manufacturing expansion and automation.



Remplir U.S. strategy on track with continued global expansion

Remplir U.S. key commercial metrics demonstrating strong growth with sales continuing to build.

Progressing towards EU/UK clearance.



US$3.5 billion[1] global nerve repair market

Material uplift in October Remplir sales – groundwork laid now translating into tangible revenue.

Approved and now selling in AUS, NZL, USA, CAN, SGP, HKG and THA.

1. Referenced papers used to estimate peripheral nerve procedures in the US per annum. Papers used included both the US and OUS databases and studies.
2. AU$39.0M as of 30 September 2026, this includes $5.2 million in cash and cash equivalents and $33.8 million in security and term deposits with maturities ranging from 3 to 12 months. No long-term secured debt facilities. The Company maintains a short-term premium funding facility used to finance insurance premiums, repaid within the policy period.

Company Strategy

Disciplined growth on four commercial fronts, backed by the capability to execute — the path to a global regenerative medicine leader and ASX 300 inclusion.

Business goal

Establish Orthocell as a global regenerative medicine leader through disciplined growth, operational excellence and a sustainable product pipeline, achieving ASX 300 inclusion

Strategic focus

- **Win in the Americas**
- Continue growth in ANZ and Asia
- Build global footprint
- Advance the product pipeline

Organisational capability

- Grow a high-performance, people-first organisation
- Build a data-enabled operating platform
- Scale world-class manufacturing capability
- End-to-end product development and commercialisation excellence


Strategic Focus

Remplir's US distribution network now spans 20+ states and roughly 72% of the population, while UK/EU market access steadily advances.

Strategic focus	**Win in the Americas**	Continue growth in ANZ and Asia	Build global footprint	Advance the product pipeline
FY27 Strategic Focus Highlights To Date	• **Built dedicated US Sales**, Medical Education and Marketing capability • **23 distributors across 20+ states**, achieving 72% coverage • 97 **hospitals purchasing Remplir** with 100+ Value Assessment Committee approvals submitted, in process or approved	• **370 surgeons across 239 Australian hospitals** have used Remplir since launch • **Nerve sparing prostate cancer opportunity building**, with 300 procedures completed • **First commercial sales in Hong Kong and Thailand**; case growth continues in Singapore	• **Humanitarian reach expanded** through an initiative delivering Remplir to war victims in Ukraine • **Remplir UK / EU market access** program progressing • **Striate+ approvals secured in Brazil**, Colombia and Ecuador	• **U.S. FDA regulatory program commenced** for SmrtWrap tendon repair • **First right of refusal secured over PearlBone™ distribution**, with increased interest in Marine Biomedical • **SmrtRope™ for ACL reconstruction: design and testing progressed, preclinical study accepted for publication**

The Lassonde Curve | Market Valuation Lifecycle

18 months post-FDA clearance, OCC is entering the inflection point of its US growth curve — with the commercial platform established and FY27 revenue growth ahead.



1. Breakeven is cash breakeven and reflects the point at which net operating cash flow is zero, based on current pricing and cost assumptions.

ortho·cell
advancing tissue repair and regeneration

Remplir™


Nerve repair, made SMRT™




- Easy to handle
- Elastic and conformable
- Supports nerve glide
- Fully resorbs

Engineered with Orthocell's proprietary SMRT™ technology to mimic human epineurium.


Remplir creates an optimal healing environment to support consistent axonal regeneration across a range of peripheral nerve procedures.



Connect



Protect




Cap

References: 1. Data on file **2.** O'Beirne, A., J. Cullen, E. Landao-Bassonga, M. Zheng, C. Lee, P. Kaluskar, A. Tai and M. Zheng (2024). "Reconstruction of Upper Extremity Peripheral Nerve Injuries Using an Epineurial-Like Collagen Device—A Prospective Clinical Study." Journal of Reconstructive Microsurgery Open 09(01): e78-e88.

Remplir Compelling Clinical Results

90% success rate in the Remplir nerve repair real world study (RWE), supporting continued US roll out and EU and UK launch. Further preclinical and clinical studies underway: nerve-sparing radical prostatectomy, Remplir with allografts, nerve capping, sutureless nerve repair and mechanistic animal studies.

Latest results from the Remplir RWE study demonstrate an overall treatment success rate of 89.7%, based on performance data from 66 patients (78 nerve procedures).




- Patients were aged 14 to 82 years, with the majority of procedures performed in the upper limb, including decompression and reconstruction of severed nerves (nerve transfer and grafting).
- No post-treatment complications or adverse effects to Remplir were reported, reinforcing its well-established safety profile and high biocompatibility, and strengthening its position as the best-performing nerve wrap in Australia.

Procedure Type	Patients (n)	Nerve Procedures (n)	Treatment Success
Motor nerve reconstruction	19	31	90.3% (28 of 31)
Nerve decompression	47	47	89.4% (42 of 47)
Total	66	78	89.7% (70 of 78)

Remplir AU/NZ Performance Since Launch[1]

Significant growth achieved since launch, with 379 surgeons and 258 hospitals[3].



1. Source: Distributor reported sales data since product launch, including quarterly unit volumes.
2. CQGR = compound quarterly growth rate.
3. Actual numbers provided by Device Technologies Australia.

Authorisation for Sale

Remplir is approved and revenue generating in seven markets, with the U.S. as the Company's focus as the world's largest market and UK and EU revenue targeted in CY27.

Market	Regulatory Evaluation	Regulatory Submission	Authorisation	Revenue Generating	Revenue Generating Target
United States, Australia, New Zealand, Singapore, Canada, Thailand, Hong Kong	●	●	●	●	
United Kingdom	●	●	○		2H CY26
Europe	●	●	○		2H CY27
Latin America	●	○			2H CY27
East Asia	○				TBD

○ In Progress ● Complete ● Revenue Generating


Remplir Prostatectomy Case Series

Adoption in Australian prostatectomy procedures is gathering momentum, with more than 300 procedures now completed and multiple surgeons routinely using the product.

Initial Remplir prostatectomy case series shows excellent early functional recovery in clinically complex patients with advanced prostate cancer

- **All patients underwent extensive removal of tumour tissue**
- **80% of patients demonstrated encouraging urinary continence outcomes** – including three who were pad-free by six months which is sooner than expected in cases like these
- **75% of patients demonstrated a return of erectile function**

Orthocell to **gather further research to strengthen clinical evidence** ahead of U.S. launch with **no further FDA approvals needed**.



1. Referenced papers used to estimate peripheral nerve procedures in the US per annum. Papers used included both the US and OUS databases and studies

ortho·cell

U.S. Remplir

Adam Wood
Chief Commercial Officer




Positive Early Momentum in FY27 for U.S. Remplir

92 Remplir units sold in October 2026 generated AU$279,000 in revenue, an 84% uplift on the Q1 FY27 monthly average of 50 units. Expanding market access, distributors and education events are accelerating growth.

Growth Drivers:


- Sales in key states drove 46% of total 92 units
- New distributors – 29% of total
- New surgeons (first case in October month) – 46% of total
- Repeat usage from surgeons and hospitals account for 44 units, 12% growth over prior month



U.S. Hospital and Surgeon Adoption Is Growing

Hospital approvals and surgeon adoption continue to grow, supported by distributor expansion, medical education and increased product awareness. Unit sales are benefiting from new customers and increased repeat use by established surgeons.


Cumulative U.S. Remplir Hospitals



November and December: TBD

October: 97 Hospitals

Cumulative U.S. Remplir Surgeons



November and December: TBD

October: 107 Surgeons

Key U.S. Activities in FY27 to Date

Our focussed in-market activities including September's major conference have contributed to strong sales to date and continue to build foundation for our future growth trajectory.



Sales

Expand, Educate, Execute

- Signed 6 new distributors and hired 2 direct sales team members
- 83 Value Analysis Committee (VAC) applications approved and first national contract signed, creating access at scale
- 15 distributors sold Remplir™ in October increasing our sales footprint



Medical Education

Clinical validation and hands-on training

- 20 events completed11 cadaver labs, 5 journal clubs, 3 conferences plus the American Society for Surgery of the Hand (ASSH) conference
- Expanded Key Opinion Leader network
- Regional meeting attendance in partnership with distributors to raise awareness in new states




Marketing

Sales enablement, multi-channel approach

- 31 new surgeons on-boarded FYTD
- Procedure-specific product materials to assist in targeted sales conversations
- Multiple online and in-person distributor training events

U.S. Remplir Commercialisation Performance

As of October, lead indicators of surgeons, hospitals and distributor coverage are all tracking ahead of expectations.



- 14 new surgeons in October contributing 46% of unit sales.
- Driven by distributor coverage, hospital access, hands-on education and peer-to-peer selling.

- Driven by VAC approvals and Remplir users now operating at multiple sites.
- Focus on large hospital groups and national contract opportunities.

- 23 distributor partners now covering 72% of the U.S. population.
- Strong surgeon relationships have resulted in early traction with Remplir.

The Four Major U.S. States Are Now Covered

With a combined population of ~114m, Orthocell has established coverage across four strategically important U.S. markets, providing a strong platform for future growth.

Florida



Recent Activity: Strong surgeon adoption with multiple large volume, influential surgeons now using the product. These surgeons also featured in our ASSH program speaking on their experience with product.

Q2 Focus: Expand surgeon usage where we have strong usage and develop centres of excellence.

First Sale	Population	Phase
Jul-25	**23M**	**Early Growth**

California



Recent Activity: Multiple labs and dinners in partnership with our Californian distributors. Key surgeon engagements with CEO in field.

Q2 Focus: Following multiple trials, focus on hospital orders and further engagement of influential surgeons who have already used the product.

First Sale	Population	Phase
Jan-26	**39M**	**Early Growth**

Texas



Recent Activity: Statewide distributor signed and Orthocell Area Sales Manager based in Texas hired who holds key surgeon relationships to support launch. Initial training and field visits completed, first case on 18 September.

Q2 Focus: Cadaveric labs for surgeon training, ongoing distributor upskilling, identify key surgeon targets and support product adoption in initial cases.

First Sale	Population	Phase
Q2 FY27	**32M**	**Initial MP**

New York



Recent Activity: Distributor signed, VAC submitted at major hospital, ongoing engagement with key surgeon, including speaking at Orthocell Australian Nerve Symposium event in 2027.

Q2 Focus: Initial distributor training, identify further key accounts and submit VAC documentation for approval.

First Sale	Population	Phase
Q2 FY27	**20M**	**Access**

2026 American Society for Surgery of the Hand Annual Conference - Innovation Forum Surgeon Presentations



"All you have is this thin **epineurial-looking layer,** which is quite beautiful."

Dr David Brogan (Washington University), describing histology at 17 weeks

Optimal healing environment



"Seeing this result [clinically], I think is helpful. Especially when using the Remplir™ device, seeing how that kind of material can **help augment the epineurium** and allow for the epineurium to form."

Dr Neill Li (Duke University), on his decision to use in nerve decompression cases

Supports nerve glide



"Now we have something like Remplir where we don't have to suture, so that **saves time and saves some costs.** It can be beneficial because if you suture too tightly, the nerve can swell. We want to do a positive thing for our patients."

Dr Michael Doarn (Florida Orthopedic Institute), on the benefits in revision carpal tunnel surgery

Elastic and conformable



"Remplir has been the one [nerve wrap] that gets me right in that category of **'just right', not too stiff, not too slimy"**

Dr Aaron Morgan (Integris Health), using a Goldilocks analogy to describe the handling of Remplir

Easy to handle

ortho·cell

Cash Management and Manufacturing

Jim Piper
Chief Financial Officer



Quarterly Cash Flow Summary

Sustainable cash reserves are in place to fund the commercialisation of Remplir and support the business to profitability, with no additional funding anticipated.

AUD $M	2Q FY26	3Q FY26	4Q FY26	1Q FY27
Receipts from customers	1.2	1.6	2.5	2.6
Payments to suppliers and employees	(7.7)	(4.9)	(6.6)	(7.3)
Government grants & net interest received	0.5	3.4	0.5	0.2
Operating cash use for the period[1]	**(6.0)**	**0.1**	**(3.6)**	**(4.5)**
Annual R&D tax refund[2]	-	(3.0)	-	-
Non-recurring expenditure (ERP, Automation, Prepaid and other one-offs)	1.0	0.4	1.2	0.6
Normalised operating cash[3]	**(5.0)**	**(2.5)**	**(2.4)**	**(3.9)**
Capital expenditure & other investments	(0.2)	(1.2)	(1.0)	(0.1)
Proceeds from fund raising and other financing	(13.4)	(0.1)	0.8	(0.5)
Funds Available[4]	**49.4**	**48.0**	**44.1**	**39.0**

- **$39.0 million in funds available** supports planned capital works, commercial execution and R&D activities.
- **Cash expenditure remains in line with expectations,** with Q1 FY27 operating cash use of $4.5M and normalised cash use of $3.9M.
- **No additional funding anticipated** to support Remplir commercialisation and fund the business to profitability.

1. Numbers may not sum due to rounding.
2. The R&D tax incentive refund is received annually, resulting in nil/lump sum amounts in individual quarters.
3. Normalised operating cash burn is a non-IFRS, unaudited measure that excludes the annual R&D tax incentive refund and non-recurring expenditure (ERP, automation, prepayments and other one-offs).
4. Funds Available comprises cash and cash equivalents, security deposits, and term deposits with maturity greater than 3 months.

Investing to Meet Future Growth

Upgrading facility to lift collagen device capacity to ~500,000 units per year, with construction starting H2 CY26 and completion scheduled for late CY2027.

Key Investments

Lab Expansion

- Investment to expand by increasing manufacturing and warehousing capacity
- Construction beginning in H2CY26 and completion scheduled late 2027

Manufacturing Automation

- Automated processing and fume-hood upgrades
- No increase to headcount in the medium term
- Enabling 24-hour operations

Key Outcomes

Secure and reliable supply chain

- Manufacturing upgrades will provide inventory to support expected growth demands
- Inventory availability unaffected during construction with stock held in the US and AU

Designed for scalable production

- Manufacturing cycle times reduced
- Improved device unit operating costs
- Four times the current device manufacturing capacity



Pipeline Update


ortho·cell

Collagen Medical Device Pipeline

Extending our collagen platform into tendon and ligament repair:
SmrtWrap™ US regulatory study starts 1H CY27, with SmrtRope™ product testing progressing through FY27.

SmrtWrap™

Tendon Repair



Collagen wrap for prevention of scarring and adhesions after tendon repair.

Status


Development of 510(k) application strategy and testing program.

FY27 Next Steps

Complete 510(k) pre-submission meeting, and regulatory study.

SmrtRope™

Ligament Repair



Collagen rope for ACL reconstruction.

Status

Preclinical study accepted for publication.

FY27 Next Steps

Commercialisation strategy and manufacturing evaluation.

*Special Access Scheme – TGA compassionate access pathway, category C (low risk, established history of use)

Marine Biomedical

Marine Biomedical has received U.S. FDA 510(k) clearance for PearlBone™, its innovative marine-derived bone graft substitute developed from sustainably sourced pearl shell

- **FDA clearance enables PearlBone to be marketed in the United States** for its cleared indications, a significant commercialisation milestone.
- Orthocell holds a **12% equity interest in Marine Biomedical, following its A$1.05 million investment,** and has a first right of refusal over global distribution of PearlBone and future bone repair and regeneration products.
- PearlBone **expands Orthocell's biologically driven portfolio into the global bone repair and regeneration market,** complementing its nerve and tendon technologies.
- Marine Biomedical is **advancing commercial readiness** ahead of the planned U.S. launch of PearlBone.



Closing highlights



Best-in-class platform for Bone, Nerve and Tendon repair now selling in nine[1] jurisdictions.

Compelling supportive clinical data.

Product margins retained in-house.

Manufacturing facility and all IP owned by the company.

Growing international revenues targeting large under penetrated markets.

We have maintained constant growth into new markets with expansion planned into the US$750 million[2] EU/UK market following expected approval in 2H CY26 .

Remplir U.S. Strategy is on-track.

Market access activities are clearly defined with execution progressing as planned and sales continuing to build.

Fully funded and investing in sales growth.

Clear path to cash breakeven requiring less than 1% U.S. market share - while maintaining a cash balance in the high $20Ms to support execution.

1. Orthocell's collagen platform of products, including Striate+™ and Remplir™.
2. EU and UK nerve repair market sizes estimated using referenced papers from both US and OUS databases and studies.

Authorised for release by
The Board of Directors of Orthocell Limited

P: +61 8 9360 2888
E: paul.anderson@orthocell.com.au

orthocell.com